Both companies separately last week announced plans to expand the scope of their respective businesses in response to what they said is increased desire from customers to outsource their array production and array-based research projects.
While revenues fell short of analysts' expectations for the quarter, the legacy Invitrogen business reported 7 percent organic revenue growth. The Q4 revenue numbers also do not include mass spec sales, which are now accounted for as an equity investment. In addition, company officials predicted 2009 organic revenue growth in the low single-digits.
Navigenics’ lower-priced program to incorporate genetic risk data in patients’ annual medical checkup raises questions as to whether personal genomics firms should be broadly marketing their services to physicians.
Details of the deal are sparse, but the partners said they hope their research will lead to the development of genetic tests that can gauge patients’ predisposition to rare diseases and help target individuals most likely to respond to drugs made by MondoBiotech.